{
    "nct_id": "NCT03280563",
    "official_title": "A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer)",
    "inclusion_criteria": "Inclusion Criteria for Both Stages:\n\n* Measurable disease per RECIST v1.1\n* Adequate hematologic and end organ function\n* Disease progression during or after first- or second-line hormonal therapy with CDK4/6 inhibitor\n\nInclusion Criteria for Stage 1:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Metastatic or inoperable, locally advanced, histologically or cytologically confirmed invasive HR-positive HER2-negative breast cancer\n* Recommended for endocrine therapy, and cytotoxic chemotherapy not indicated at study entry\n* Recurrence or progression following most recent systemic breast cancer therapy\n* Disease progression during or after first- or second-line hormonal therapy for locally advanced or metastatic disease\n* Postmenopausal according to protocol-defined criteria\n* Life expectancy >3 months\n* Available tumor specimen for determination of PD-L1 status\n\nInclusion Criteria for Stage 2:\n\n* ECOG performance status of 0-2\n* Ability to initiate treatment within 3 months after disease progression or unacceptable toxicity on a Stage 1 regimen\n\nExclusion Criteria for Both Stages:\n\n* Significant or uncontrolled comorbid disease as specified in the protocol\n* Uncontrolled tumor-related pain\n* Autoimmune disease except for stable/controlled hypothyroidism, Type 1 diabetes mellitus, or certain dermatologic conditions\n* Positive human immunodeficiency virus test\n* Active hepatitis B or C\n* Active tuberculosis\n* Severe infection within 4 weeks and/or antibiotics within 2 weeks prior to study treatment\n* Prior allogeneic stem cell or solid organ transplantation\n* History of malignancy other than breast cancer within 2 years prior to screening except those with negligible risk of metastasis/death\n* History of or known hypersensitivity to study drug or excipients\n* For patients entering Stage 2, recovery from all immunotherapy-related adverse events to Grade 1 or better or to baseline at the time of consent\n\nExclusion Criteria for Stage 1:\n\n* Prior fulvestrant or cytotoxic chemotherapy for metastatic breast cancer, or certain other agents as specified in the protocol\n* Unresolved AEs from prior anti-cancer therapy\n* Eligibility only for the control arm\n* Prior treatment with inhibitors as specified in the protocol\n\nExclusion Criteria for Stage 2:\n\n* Unacceptable toxicity with atezolizumab during Stage 1\n* Uncontrolled cardiovascular disease or coagulation disorder, including use of anticoagulants as specified in the protocol\n* Significant abdominal or intestinal manifestations within 6 months prior to treatment\n* Grade 2 or higher proteinuria\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}